Cannabis tolerance reduces symptom relief
Frontiers in Pharmacology · 19.06.2025 · 16
DOI: 10.3389/fphar.2025.1496232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.06.2025. Verfasst von Sarah S Stith und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics, University of New Mexico, Albuquerque, NM, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
We measure for the first time how tolerance from repeated consumption of medical cannabis affects acute symptom management.
Methods
Using the Releaf App, medical cannabis patients recorded their symptoms, product type, cannabis consumption method, major cannabinoid levels, dosing patterns, and real-time symptom intensity levels prior to and following each cannabis administration session, as well as any side effects from usage. The sample consists of the first ten cannabis self-administration sessions recorded by 16,395 medical cannabis patients between 06/05/2016 and 09/19/22, yielding a sample of 120,691 symptom-specific treatment-level observations, recorded during 42,005 sessions. This study uses fixed effects least-squares regression analyses to analyze the effects of the session count on symptom relief.
Results
On average, people experienced a 0.5% decrease in symptom relief with each subsequent session (p < 0.001). Combustible products offered more therapeutic relief than vaping, eating or drinking; higher doses offered greater relief; and the reduction in symptom relief with subsequent usage was similar whether patients were treating pain, depression, or anxiety. Cannabis products’ THC levels were positively associated with symptom relief; however, patients showed no changes in the THC levels of products with subsequent consumption. Patients increased the dose consumed as they completed more sessions. The results are robust to alternative treatment measures, including days since the first session was recorded. Subsample regressions indicate that experienced users drive most of the effects. Analyses assessing side effects show that factors, such as THC and dose, that increased symptom relief also increased side effects experienced. Conclusion and implications The findings suggest the majority of patients experience decreased symptom relief after repeated use of medical cannabis, counterbalanced by improvements in negative side effects. Of direct clinical relevance, THC levels and the dose can be adjusted to customize medical cannabis patient treatment, increase medication compliance, and improve treatment outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Economics, University of New Mexico, Albuquerque, NM, United States.
- MoreBetter, Ltd., Hyattsville, MD, United States.
- Department of Psychology, University of New Mexico, Albuquerque, NM, United States.
Zitieren
APA
Stith, S. S., Li, X., Brockelman, F., Keeling, K., Hall, B., & Vigil, J. M. (2025). Cannabis tolerance reduces symptom relief. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1496232
Vancouver
Stith SS, Li X, Brockelman F, Keeling K, Hall B, Vigil JM. Cannabis tolerance reduces symptom relief. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1496232
BibTeX
@article{Stith2025,
author = {Stith, Sarah S and Li, Xiaoxue and Brockelman, Franco and Keeling, Keenan and Hall, Branden and Vigil, Jacob M},
title = {Cannabis tolerance reduces symptom relief},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1496232}
}
EUVIMED